M. Ojima

发表

Combined effects of the angiotensin II antagonist candesartan cilexetil (TCV-116) and other classes of antihypertensive drugs in spontaneously hypertensive rats.

Y. Inada, K. Nishikawa, T. Wada, 1996, Hypertension research : official journal of the Japanese Society of Hypertension.

Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor.

K. Kubo, Y. Inada, Y. Shibouta, 1997, European journal of pharmacology.

Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl

K. Kubo, Y. Inada, Masakuni Noda, 1993, The Journal of pharmacology and experimental therapeutics.

Pharmacologic properties of candesartan cilexetil—possible mechanisms of long-acting antihypertensive action

Y. Inada, K. Nishikawa, M. Ojima, 1999, Journal of Human Hypertension.

Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats.

K. Kubo, Y. Inada, T. Naka, 1994, The Journal of pharmacology and experimental therapeutics.

Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats.

Y. Inada, Y. Shibouta, K. Nishikawa, 1996, Hypertension research : official journal of the Japanese Society of Hypertension.

Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist.

K. Kubo, Y. Inada, T. Naka, 1993, Biochemical pharmacology.

Regional Hemodynamic Effects of Candesartan Cilexetil (TCV-116), an Angiotensin II AT₁-Receptor Antagonis , in Conscious Spontaneously Hypertensive Rats

Yoshiyuki, Yoshiyuki, Tsukasa, 2006 .

Regional hemodynamic effects of candesartan cilexetil (TCV-116), an angiotensin II AT1-receptor antagonist, in conscious spontaneously hypertensive rats.

Y. Inada, T. Wada, T. Sanada, 1997, Japanese journal of pharmacology.

Effect of an angiotensin II receptor antagonist, CV-11974, and its prodrug, TCV-116, on production of aldosterone.

Y. Inada, M. Noda, Y. Shibouta, 1994, European journal of pharmacology.

Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazoles.

K. Kubo, Y. Inada, T. Naka, 1993, Journal of medicinal chemistry.

In Vitro Antagonistic Properties of a New Angiotensin Type 1 Receptor Blocker, Azilsartan, in Receptor Binding and Function Studies

K. Kusumoto, H. Igata, K. Kubo, 2011, Journal of Pharmacology and Experimental Therapeutics.

Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats.

Y. Fujisawa, Y. Inada, Y. Ishimura, 1997, Clinical and experimental hypertension.

Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.

K. Kusumoto, H. Igata, F. Yamaguchi, 2011, European journal of pharmacology.

Pharmacological profile of a novel nonpeptide angiotensin II subtype 1 receptor antagonist, TCV-116.

K. Kubo, Y. Inada, T. Naka, 1994, Blood pressure. Supplement.

Effects of delapril on stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats.

A. Shino, Y. Inada, K. Nishikawa, 1995, Drugs under experimental and clinical research.